Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 14, 2015; 21(42): 12083-12090
Published online Nov 14, 2015. doi: 10.3748/wjg.v21.i42.12083
Published online Nov 14, 2015. doi: 10.3748/wjg.v21.i42.12083
Management of hepatitis B virus infection after liver transplantation
Miguel Jiménez-Pérez, Rocío González-Grande, José Mostazo Torres, Carolina González Arjona, Liver Transplantation and Hepatology Unit, UGC de Aparato Digestivo Hospital Regional Universitario, 29010 Malaga, Spain
Francisco Javier Rando-Muñoz, Department of Abdominals Diseases, Hospital Nij Smellinghe Ziekenhuis, 9202 NN Drachten, The Netherlands
Author contributions: Jiménez-Pérez M, González-Grande R, Mostazo Torres J, González Arjona C and Rando-Muñoz FJ contributed equally to this work.
Conflict-of-interest statement: The authors have no conflict of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Miguel Jiménez-Pérez, MD, Liver Transplantation and Hepatology Unit, UGC de Aparato Digestivo Hospital Regional Universitario, Avenida Carlos Haya, 29010 Malaga, Spain. mjimenezp@commalaga.com
Telephone: + 34-6-1095935 Fax: + 34-95-1291941
Received: April 18, 2015
Peer-review started: April 20, 2015
First decision: June 23, 2015
Revised: July 4, 2015
Accepted: September 14, 2015
Article in press: September 14, 2015
Published online: November 14, 2015
Peer-review started: April 20, 2015
First decision: June 23, 2015
Revised: July 4, 2015
Accepted: September 14, 2015
Article in press: September 14, 2015
Published online: November 14, 2015
Core Tip
Core tip: The current success of liver transplantation in patients with chronic hepatitis B (CHB)-related cirrhosis is mainly due to the use of prophylaxis with hepatitis B immunoglobulins (HBIG) and oral antivirals against post-liver transplant recurrence of CHB. The combination of low-dose HBIG plus antivirals forms the current standard prophylaxis. The use of newer antivirals (entecavir and tenofovir), coupled with better understanding of the predisposing factors for recurrence of CHB, has led to new perspectives for prophylaxis regimens, aimed at withdrawal of HBIG or the use of HBIG-free regimens, oriented toward a strategy of individualized prophylaxis.